Determination of ethyl biscoumacetate and its metabolite 7-hydroxyethyl biscoumacetate in human serum by high-performance liquid chromatography and mass spectrometry.
An efficient reversed-phase high-performance liquid chromatographic method has been developed for the determination of ethyl biscoumacetate (EBA) and its metabolite in human serum, using the mu Bondapak C18 column and methanol-water-phosphoric acid (56:46.8:0.2, v/v/v) as the mobile phase. This method permitted the determination of both EBA and a metabolite in human serum. The latter has been mentioned by other authors only in urine samples, where significant concentrations were found. Identification of the metabolite as 7-hydroxyethyl biscoumacetate was based on its chromatographic separation, followed by isolation from the eluate and direct mass spectrometric identification. It has been found that the higher EBA concentrations in human serum described by Brodie et al. [J. Pharmacol. Exp. Ther., 106 (1952) 453] were caused by the insufficient resolving power of the spectrophotometric method used, leading to overlapping of the UV spectra of the parent drug and its metabolite.
Pospísil
J
J
Department of Clinical Pharmacology, Charles University, Prague, Czechoslovakia.
Patzelová
V
V
Perlík
F
F
D002851:Chromatography, High Pressure Liquid; D005017:Ethyl Biscoumacetate / Q000031:analogs & derivatives* / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D013058:Mass Spectrometry; D015203:Reproducibility of Results
D005017:Ethyl Biscoumacetate; C075557:7-hydroxyethyl biscoumacetate